Secondary prevention after coronary artery bypass grafting - What do we know?

Scandinavian Cardiovascular Journal

Volumn 38, Issue 2, 2004, Pages 69-74

  Herlitz, Johan ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Coronary artery bypass grafting; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOBUFEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; MEVINOLIN; PLACEBO; PROTHROMBIN; RAMIPRIL; TICLOPIDINE; VERAPAMIL; WARFARIN;

ANGINA PECTORIS; ANTICOAGULANT THERAPY; ARTICLE; ATHEROSCLEROSIS; BEHAVIOR DISORDER; BEHAVIOR MODIFICATION; BLEEDING DISORDER; CARDIOVASCULAR DISEASE; CHOLESTEROL INTAKE; CIGARETTE SMOKING; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DRUG EFFICACY; GRAFT PATENCY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; LIFESTYLE; MORTALITY; PRIORITY JOURNAL; PROTHROMBIN TIME; PSYCHOTHERAPY; RECURRENT DISEASE; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SMOKING CESSATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TYPE A BEHAVIOR;

COMBINED MODALITY THERAPY; CORONARY ARTERY BYPASS; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INCIDENCE; LIFE STYLE; MALE; MYOCARDIAL INFARCTION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RECURRENCE; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 2542503607     PISSN: 14017431     EISSN: None     Source Type: Journal    
DOI: 10.1080/14017430410026269     Document Type: Article

References (74)

1. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344: 563-570.
2. Hultgren HN, Peduzzi P, Detre K, et al. and the Study Participants. The 5 year effect of bypass surgery on relief of angina and exercise performance. Circulation 1985; 72(Suppl V): 79-83.
3. Blumenthal JA, Mark DB. Quality of life and recovery after cardiac surgery [editorial comment]. Psychosom Med 1994; 56: 213-215.
4. Bradshaw PJ, Jamrozik K, Le M, Gilfillan I, Thompson PL. Mortality and recurrent cardiac events after coronary artery bypass graft: Long term outcomes in a population study. Heart 2002; 88: 488-494.
5. Rahimtoola SH, Fessler CL, Grunkemeier GL, et al. Survival 15 to 20 years after coronary artery bypass surgery for angina. J Am Coll Cardiol 1993; 21: 151-157.
6. Boylan MJ, Lytle BW, Loop FD, et al. Surgical treatment of isolated left anterior descending coronary stenosis. Comparison of left internal mammary artery and venous autograft at 18 and 20 years of follow-up. J Thorac Cardiovasc Surg 1994; 107: 657-662.
7. Jones RH, Kesler K, Phillips HRI, et al. Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. J Thorac Cardiovasc Surg 1996; 111: 1013-1025.
8. Sergeant PT, Blackstone EH, Meyns BP. Does arterial revascularization decrease the risk of infarction after coronary artery bypass grafting? Ann Thorac Surg 1998; 66: 1-11.
9. Myers WO, Blackstone EH, Davis K, et al. CASS registry long term surgical survival. Coronary artery surgery study. J Am Coll Cardiol 1999; 33: 488-498.
10. Cameron AA, Davis KB, Rogers WJ. Recurrence of angina after coronary artery bypass surgery: Predictors and prognosis (CASS Registry). J Am Coll Cardiol 1995; 4: 895-899.
11. Herlitz J, Brandrup-Wognsen G, Haglid M, Karlson BW, Hartford M, Karlsson T. Predictors of death during 5 years after coronary artery bypass grafting. Int J Cardiol 1998; 64: 15-23.
12. Domanski MJ, Borkowf CB, Campeau L, et al. and the Post CABG Trial Investigators. Prognostic factors for atherosclerosis progression in saphenous vein grafts. The Postcoronary Artery Bypass Graft (Post-CABG) Trial. J Am Coll Cardiol 2000; 36: 1877-1883.
13. Loop FD, Golding LR, MacMillan JP, Cosgrove DM, Lytle BW, Sheldon WC. Coronary artery surgery in women compared with men: Analyses of risks and long-term results. J Am Coll Cardiol 1983; 1: 383-390.
14. Aronson S, Boisvert D, Lapp W. Isolated systolic hypertension is associated with adverse outcomes from coronary artery bypass grafting surgery. Anesth Analg 2002; 94: 1079-1084.
15. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
16. Sacks FM, Pfeffer MA, Moye LA, et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
17. Bittner V, Hardison R, Kelsey SF, Weiner BH, Jacobs AK, Sopko G. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 2002; 106: 2537-2542.
18. Knatterud GL, Rosenberg Y, Campeau L, et al. and Post CABG Investigators. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the Post Coronary Artery Bypass Graft Trial. Circulation 2000; 102: 157-165.
19. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease. Pathogenesis, predisposition, and prevention. Circulation 1998; 97: 916-931.
20. Blankenhorn DH, Nessim, SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233-3240.
21. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipolniacin on coronary atherosclerosis: A 4-year follow-up. JAMA 1990; 264: 3013-3017.
22. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801-807.
23. Hjalmarson Å, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 1981; ii: 823-827.
24. Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17: 76-81.
25. The MACB Study Group. Effect of metoprolol on death and cardiac events during a 2-year period after coronary artery bypass grafting. Eur Heart J 1995; 16: 1825-1832.
26. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Are beta-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial infarction? Arch Intern Med 2000; 160: 947-952.
27. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS II). Lancet 1999; 353: 9-13.
28. Merrit HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
29. Packer M, Coats AJS, Fowler MB, et al. for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
30. Goldman S, Copeland J, Moritz T, et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: Results of a Veterans Administration Cooperative Study. Circulation 1988; 6: 1324-1332.
31. Goldman S, Copeland J, Moritz T, et al. Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy results of a Veterans Administration Cooperative Study. Circulation 1989; 80: 1190-1197.
32. Stein PD, Dalen JE, Goldman S, Schwartz L, Theroux P, Turpie AGG. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Chest 1995; 108: 424S-430S.
33. Goldman S, Copeland J, Moritz T, et al. Long-term graft patency (3 years) after coronary artery surgery: Results of a VA cooperative study. Circulation 1994; 89: 1138-1143.
34. Dacey LJ, Munoz JJ, Johnson ER, et al. for the Northern New England Cardiovascular Disease Study Group. Effect of preoperative aspirin use on mortality in coronary artery bypass grafting patients. Ann Thorac Surg 2000; 70: 1986-1990.
35. Mangano DT, for the Multicenter Study of perioperative ischemia research group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347: 1309-1317.
36. Ratnatunga CP, Edmondson SF, Rees GM, Kovacs IB. High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation. Circulation 1992; 85: 1077-1082.
37. Zimmermann N, Weak A, Kim U, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542-547.
38. Buchanan MR, Brister SJ. Individual variation in the effects of aspirin on platelet function: Implication or the use of ASA clinically. Can J Cardiol 1995; 11: 221-227.
39. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
40. The SINBA Group (Studio Indobufene nel Bypass Aortocoronarico). Indobufen versus aspirin plus dipyridamole after coronary artery bypass surgery. Coron Artery Dis 1991; 2: 897-906.
41. Rajah SM, Nair U, Rees M, et al. Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994; 107: 1146-1153.
42. Chevigne M, David JL, Rigo P, Limet R. Effect of ticlopidine on saphenous vein bypass patency rates: A double-blind study. Ann Thorac Surg 1984; 37: 371-378.
43. Limet R, David JL, Magotteaux P, Larock MP, Rigo P. Prevention of aortocoronary bypass graft occlusion: Beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: A double-blind study. J Thorac Cardiovasc Surg 1987; 94: 773-783.
44. CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet 1996; 348: 1329-1339.
45. Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001; 103: 363-368.
46. The Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
47. Chesebro JH, Clements IP, Fuster V. A platelet-inhibitor-drug trial in coronary-artery bypass operations. Benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. N Engl J Med 1982; 307: 73-78.
48. Chesebro JH, Fuster V, Elveback LR, et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med 1984; 310: 209-214.
49. Rajah SM, Salter MCP, Donaldson DR, et al. Acetylsalicylic acid and dipyridamole improve the early patency of aorta-coronary bypass grafts. J Thorac Cardiovasc Surg 1985; 90: 373-377.
50. Ekeström SA, Gunnes S, Brodin UB. Effect of dipyridamole (persantin) on blood flow and patency of aortocoronary vein bypass grafts. Scand J Thorac Cardiovasc Surg 1990; 24: 191-196.
51. Gohlke H, Gohlke-Barwolf C, Sturzenhofecker P, et al. Improved graft patency with anticoagulant therapy after aortocoronary bypass surgery: A prospective, randomized study. Circulation 1981; 64(Suppl II): II-22-II-27.
52. van der Meer J, Hillege HL, Kootstra GJ, et al. for the CABADAS research group. Prevention of one-year vein graft occlusion after aortocoronary bypass surgery: A comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. Lancet 1993; 342: 257-264.
53. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336: 153-162.
54. Huynh T, Théroux P, Bogaty P, Nasmith J, Solymoss S. Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation 2001; 103: 3069-3074.
55. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
56. Kjoller-Hansen L, Steffensen R, Grande P. The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). J Am Coll Cardiol 2000; 35: 881-888.
57. Oosterga M, Voors AA, Pinto YM, et al. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). Quinapril on Vascular Ace and Determinants of Ischemia. Am J Cardiol 2001; 87: 542-546.
58. Cavender JB, Rogers WJ, Fisher LD, Gersh BJ, Coggin CJ, Myers WO. Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10 year follow-up. J Am Coll Cardiol 1992; 20: 287-294.
59. Voors AA, van Brussel BL, Plokker T, et al. Smoking and cardiac events after venous coronary bypass surgery. A 15-year follow-up study. Circulation 1996; 93: 42-44.
60. van Domburg RT, Meeter K, van Berkel DFM, Veldkamp RF, van Herwerden LA, Bogers AJJC. Smoking cessation reduces mortality after coronary artery bypass surgery: A 20-year follow-up study. J Am Coll Cardiol 2000; 36: 878-883.
61. Burell G. Group psychotherapy in project new life: Treatment of coronary-prone behaviors for patients who have had coronary artery bypass graft surgery. Heart and Mind in: Allan R & Scheidt S (Eds.): Heart and Mind: The Practice of Cardiac Psychology. Washington D.C. American Psychological Association 1996: pp. 291-310.
62. From Attebring M, Hartford M, Holm G, Wiklund O, Wahrborg P, Herlitz J. Risk indicators for recurrence among patients with coronary artery disease. Scand Cardiovasc J 1998; 32: 9-16.
63. From Attebring M, Hartford M, Berndt AK, Herlitz J. Has interest in secondary prevention increased among physicians after the 4S study? Scand Cardiovasc J 2000; 34: 164-167.
64. Irving RJ, Oram SH, Boyd J, Rutledge P, McRae F, Bloomfield P. Ten year audit of secondary prevention in coronary bypass patients. BMJ 2000; 321: 22-23.
65. Allen JK, Blumenthal RS, Margolis S, Young DR. Status of secondary prevention in patients undergoing coronary revascularization. Am J Cardiol 2001; 87: 1203-1206.
66. Belcher PR, Gaw A, Cooper M, Brown M, Wheatley DJ, Lindsay GM. Are we negating the benefits of CABG by forgetting secondary prevention? J Human Hypertension 2002; 16: 691-697.
67. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995-1001.
68. Baltali M, Kiziltan HT, Korkmaz ME, et al. Prevalence of modifiable cardiovascular risk factors remain high after coronary bypass graft surgery: A multicentre study among Turkish patients. J Cardiovasc Risk 2002; 9: 207-214.
69. Caulin-Glaser T, Blum M, Schmeizl R, Prigerson HG, Zaret B, Mazure CM. Gender differences in referral to cardiac rehabilitation programs after revascularization. J Cardiopulmonary Rehabil 2001; 21: 24-30.
70. Stagmo M, Westin L, Carlsson R, Israelsson B. Long-term effects on cholesterol levels and the utilization of lipid-lowering drugs of a hospital-based programme for secondary prevention of coronary artery disease. J Cardiovasc Risk 2001; 8: 243-248.
71. Herlitz J, Brandrup-Wognsen G, Emanuelsson H, et al. Mortality and morbidity in diabetic and nondiabetic patients during a 2-year period after coronary artery bypass grafting. Diabetes Care 1996; 19: 698-703.
72. Barzilay JL, Kronmal RA, Bittner V, Eaker E, Evans C, Foster ED. Coronary artery disease and coronary artery bypass grafting in diabetic patients aged ≥65 years (report from the coronary artery surgery study CASS registry). Am J Cardiol 1994; 74: 334-339.
73. The BARI Investigators. Influence of diabetes on 5 year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. Circulation 1997; 96: 1761-1769.
74. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977-986.